Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pattern-recognition receptors (PRRs) for double-stranded RNA (dsRNA) are a critical class of innate immune sensors that detect viral replication or cellular distress [1, 4]. This group includes endosomal receptors like Toll-like receptor 3 (TLR3) and cytosolic sensors such as Retinoic acid-inducible gene I (RIG-I) and Melanoma differentiation-associated protein 5 (MDA5) [2, 3]. Upon binding to dsRNA, these receptors trigger signaling cascades involving adapter proteins like TRIF or MAVS, leading to the production of Type I interferons and pro-inflammatory cytokines [4]. In clinical applications, dsRNA PRR agonists are being developed as vaccine adjuvants and cancer immunotherapies to enhance the body's anti-tumor response by converting "cold" tumors into "hot" ones [5]. Conversely, dysregulation of these sensors is linked to autoimmune and autoinflammatory disorders, such as Aicardi-Goutières syndrome, making them potential targets for inhibitory therapies [4]. These receptors also play roles in regulating cell death and autophagy in response to viral infection [5].
Agonists of dsRNA pattern-recognition receptors mimic viral infection by binding to conserved domains in sensors such as TLR3, RIG-I, or MDA5. This binding triggers the recruitment of adapter proteins (TRIF for TLR3; MAVS for RLRs), which activate downstream kinases such as TBK1 and IKK-epsilon. These kinases phosphorylate transcription factors IRF3 and IRF7, leading to their translocation to the nucleus and the subsequent induction of Type I interferons (IFN-alpha/beta) and pro-inflammatory cytokines, which stimulate both innate and adaptive immune responses [4, 5].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pattern-recognition receptor for double-stranded RNA (dsRNA PRR).